Lauren Hackett named deputy director of administration at Albert Einstein Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Lauren Hackett was named deputy director of administration of Albert Einstein Cancer Center and associate vice president of cancer medicine at Montefiore Medicine. 

Hackett, who is currently the chief operating officer at the Allen Institute, will assume these roles in August 2021.  

At AECC, Hackett will have oversight and authority over the administrative team and structure, running all aspects of its operations. A key part of her role is partnering with the senior leaders at AECC, Einstein, and Montefiore to align and implement strategic priorities across its cancer enterprise.  

As COO at the Allen Institute, a private, non-profit research institute, she led the institute through the COVID-19 pandemic and co-developed the institute’s diversity, equity, and inclusion initiative. She also partnered with colleagues to integrate scientific strategy and planning efforts throughout administration and operations teams across the institute.  

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login